Business Wire

THALES

2.6.2021 09:02:13 CEST | Business Wire | Press release

Share
Majority of Businesses Still Have Remote Working Cybersecurity Concerns One Year Into the Pandemic, Finds Thales

Despite being over a year into remote working and looking ahead to likely shifts to hybrid remote/in-office working models, four fifths (82%) of businesses still remain concerned about the security risks of employees working remotely.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005100/en/

This is just one of the key insights from the 2021 Thales Global Data Threat Report, a commissioned study conducted by 451 Research, part of S&P Global Market Intelligence, which reveals that managing security risks is undoubtedly getting more challenging, with nearly half (47%) of businesses seeing an increase in the volume, severity, and/or scope of cyber-attacks in the past 12 months.

Attacks On The Rise

In fact, of those who have ever experienced a breach, two in five (41%) happened in the last year. This number has nearly doubled from 21% in 2019, marking a significant shift in the threat posed.

Globally, malware (54%) is the leading source of security attacks, followed by ransomware (48%), and phishing (41%). Yet, when it comes to how attacks occur, the message is clear: internal threats and human error are still of great concern to industry. A third of businesses stated that malicious insiders (35%) and human error (31%) are the greatest risks to them, followed by external attackers (22%).

Despite the increased risk remote working has posed to enterprises throughout the pandemic, nearly half (46%) of businesses report that their security infrastructure was not prepared to handle the risks caused by Covid-19. In fact, only one in five (20%) of organisations believe it was very prepared.

Multiple Industries at Risk

This lack of protection is affecting some industries more than others it seems, with just under two thirds (61%) of retailers surveyed experiencing a breach or failing an audit involving data and applications stored in the cloud in the past year – the most of any industry surveyed. Over half of organisations in the legal (57%), call centre (55%), transportation (54%), and telecommunications (52%) sectors also suffered the same fate in the last 12 months.

Multicloud Complexity Increases Risks

As increases in attacks continue, businesses are turning to the cloud to store their data in this digital-first world. Half (50%) of businesses report that more than 40% of their data is stored in external cloud environments. Despite this, only 17% of businesses have encrypted at least half of their sensitive data stored in the cloud. On top of this, complexity is an increasing issue, with many respondents now using at least two PaaS (Platform as a Service) providers (45%) and/or two IaaS providers (Infrastructure as a Service). A quarter (27%) of businesses are currently using more than 50 SaaS (Software as a Service) apps.

Sebastien Cano, Senior Vice President for Cloud Protection and Licensing activities at Thales comments: “Teams across the globe have faced huge security challenges over the last year as companies accelerated their digital transformation and cloud adoption initiatives. When migrating to multicloud solutions, data management can quickly spiral out of control. Organisations not only risk losing track of where their data is stored across multicloud environments but also fail to protect sensitive data in the cloud. With once unprecedented amounts of data now being used and stored in the cloud, it is vital that businesses deploy a robust security strategy based on data discovery, protection and control.”

Future Challenges and the Road Ahead

Companies are recognising the issues they are facing and are attempting to address them with Zero Trust strategies. More than three quarters (76%) of respondents’ cloud strategy reportedly rely to some degree on Zero Trust security. Almost half (44%) of respondents selected Zero Trust network access (ZTNA)/software-defined perimeter (SDP) as the leading technology to invest in during the pandemic. This was followed by cloud-based access management (42%) and conditional access (41%). In fact, a third (30%) of global respondents claim to have a formal Zero Trust strategy and, interestingly, those with a formal Zero Trust strategy are less likely to also report having been breached.

However, despite businesses making moves to stop current threats, worries are growing about future challenges on the horizon. Looking ahead, 85% of global respondents are concerned about the security threats of quantum computing, a threat arguably exacerbated by the increasing complexity of cloud environments.

Eric Hanselman, Chief Analyst at 451 Research, part of S&P Global Market Intelligence added: “The native controls and protections available in cloud environments address a set of necessary capabilities, but they’re often insufficient to deliver effective protections for sensitive data and workloads, especially when it comes to compliance with regulations such as GDPR and the implications of the Schrems II ruling. Organisations need to increase their use of encryption and ensure they take full advantage of encryption’s benefits by controlling the secrets that protect their data through BYOK (Bring Your Own Key), HYOK (Hold Your Own Key) or BYOE (Bring Your Own Encryption) approaches. Organisations also need to make internal changes to ensure that personnel at all levels understand the security challenges and to properly align investment priorities. Senior executives need to obtain a more complete understanding of the levels of risk and attack activity that their front-line staff are experiencing.”

Thales and 451 Research will discuss the findings in more detail during its upcoming Crypto Summit on 16 June 2021. To join, please visit the registration page .

About the 2021 Thales Global Data Threat Report

The 2021 Thales Global Data Threat Report was based on a global 451 Research survey commissioned by Thales of more than 2,600 executives with responsibility for or influence over IT and data security. Respondents were from 16 countries: Australia, Brazil, France, Germany, Hong Kong, India, Japan, Mexico, Netherlands, New Zealand, Singapore, South Korea, Sweden, the United Arab Emirates, the United Kingdom, and the United States. Organisations represented a range of industries, with a primary emphasis on healthcare, financial services, retail, technology, and federal government. Job titles ranged from C-level executives including CEO, CFO, Chief Data Officer, CISO, Chief Data Scientist, and Chief Risk Officer, to SVP/VP, IT Administrator, Security Analyst, Security Engineer, and Systems Administrator. Respondents represented a broad range of organizational sizes, with the majority ranging from 500 to 10,000 employees. The survey was conducted in January - February 2021.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye